Elite Pharma reports pivotal generic study success
Elite Pharmaceuticals reported positive results from a pivotal bioequivalence study for an undisclosed generic anticonvulsant.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Elite Pharmaceuticals reported positive results from a pivotal bioequivalence study for an undisclosed generic anticonvulsant. The study showed the generic is bioequivalent to the branded drug, meaning it delivers the same amount of active ingredient into the bloodstream under the test conditions.
The trial used an open-label, randomized, two-period crossover design in healthy adults under fasting conditions, which is a standard approach for bioequivalence work. Elite is now compiling the data to file an Abbreviated New Drug Application with the US Food and Drug Administration, the key regulatory step needed to market the product in the United States.
IQVIA reported combined branded and generic product sales for this market of $840 million for the twelve months ending April 2026, highlighting the commercial scale of the opportunity if Elite’s generic ultimately secures approval and market access.
Positive
- Pivotal bioequivalence success: Elite’s generic anticonvulsant met bioequivalence criteria versus the branded product, clearing a key development hurdle and enabling preparation of an Abbreviated New Drug Application with the FDA.
- Large reference market: IQVIA reported combined branded and generic sales of $840 million for the twelve months ending April 2026, indicating a commercially meaningful market if Elite’s product eventually launches.
Negative
- Regulatory and timing uncertainty: Elite highlights that FDA approval of the planned ANDA, and its timing, are uncertain, with potential delays and other factors outside the company’s control that could affect when or whether the product reaches market.
Insights
Successful bioequivalence study positions Elite for an ANDA in an $840M market.
Elite Pharmaceuticals has completed a pivotal bioequivalence study showing its undisclosed generic anticonvulsant matches the reference product. Bioequivalence is the main clinical hurdle for many generics; clearing it allows the company to move toward an Abbreviated New Drug Application with the FDA.
The press release cites IQVIA data showing combined branded and generic sales of $840 million for the twelve months ending April 2026. For a niche generic developer, a product in a market of that size can be meaningful, depending on pricing and eventual market share.
Regulatory risk remains, since FDA approval is not assured and timing is uncertain. Subsequent company filings will indicate when the ANDA is submitted and whether the FDA requests additional studies or information, which will shape the product’s path to commercialization.
8-K Event Classification
Key Figures
Key Terms
bioequivalence study medical
Abbreviated New Drug Application regulatory
anticonvulsant medical
cGMP regulatory
forward-looking statements regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Elite Pharmaceuticals (ELTP) announce in its latest 8-K?
How large is the target market for Elite Pharmaceuticals’ new generic anticonvulsant?
What does bioequivalence mean for Elite Pharmaceuticals’ generic drug candidate ELTP?
What regulatory step is Elite Pharmaceuticals (ELTP) planning after this bioequivalence study?
Does the Elite Pharmaceuticals (ELTP) announcement guarantee FDA approval of the generic anticonvulsant?
What kind of study design did Elite Pharmaceuticals use for its bioequivalence trial?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported)
ELITE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| OTCQB |
Item 7.01 Regulation FD Disclosure.
In a press release on June 15, 2026, Elite Pharmaceuticals, Inc., or Elite, reported positive results from a pivotal bioequivalence study for an undisclosed generic drug product in a class of medications called anticonvulsants. The results indicate that the generic product is bioequivalent to the branded product.
The studies conducted were open-label, randomized, balanced, single oral dose, two-treatment, two-period, two-sequence, crossover bioequivalence studies in normal, healthy, adult, human subjects under fasting conditions. The results indicated that the generic product is bioequivalent to the branded product. Elite is compiling the data for this product to file an Abbreviated New Drug Application with the US Food and Drug Administration.
A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this Item 7.01 and contained in the press release furnished as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and is not incorporated by reference into any of Elite’s filings under the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.
Caution Concerning Forward-Looking Statements
This Current Report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Including those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this current report, readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, Elite’s ability to obtain FDA approval of the ANDA or the timing of such approval process, delays, uncertainties, inability to obtain necessary ingredients and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements are not guarantees of future action or performance, the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, intellectual property protections and defenses, are discussed in Elite’s filings with the Securities and Exchange Commission, including its reports on Forms 10-K, 10-Q and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release dated June 15, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: June 15, 2026 | ELITE PHARMACEUTICALS, INC. | |
| By: | /s/ Nasrat Hakim | |
| Nasrat Hakim, President and CEO | ||
Exhibit 99.1
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
NORTHVALE, N.J. – June 15, 2026 – Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today reported positive results from a pivotal bioequivalence study for an undisclosed anticonvulsant generic drug product.
IQVIA reported branded and generic product sales for the twelve months ending April 2026 of $840 million.
The studies conducted were open-label, randomized, balanced, single oral dose, two-treatment, two-period, two-sequence, crossover bioequivalence studies in normal, healthy, adult, human subjects under fasting conditions. The results indicated that the generic product is bioequivalent to the branded product. Elite is compiling the data for this product to file an Abbreviated New Drug Application with the US Food and Drug Administration.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. Elite’s product lines consist of immediate-release and controlled-release, solid oral dose products, which are marketed under the Elite Laboratories label, as well as pursuant to licenses granted to third-party pharmaceutical marketing and distribution organizations. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties, and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite’s filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations
518-398-6222
Dianne@elitepharma.com